Nov 17: AstraZeneca scored a first-in-class approval for its pan-AKT inhibitor capivasertib as a treatment for adults with hormone receptorpositive and HER2-negative locally advanced or metastatic breast cancer whose tumors also have PIK3CA, AKT1 or PTEN mutations
Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease
Changes and Cancellations : Same-day cancellations or changes will incur a cancellation fee
Research Insight: The central nervous system effects of GLP-1, particularly on appetite regulation and reward pathways, are well-documented, showing a direct reduction in caloric intake
Significant acceleration in wound repair was evident on Days 7 and 11 ( p 2log 10 within 12 hours [168]
A new study in JAMA Oncology warns that GLP-1 receptor agonists like Ozempic and Mounjaro may raise the risk of kidney cancer, even though they seem to lower the risk of other cancers